Cargando…
Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated”
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
by the American Academy of Dermatology, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961936/ https://www.ncbi.nlm.nih.gov/pubmed/35364217 http://dx.doi.org/10.1016/j.jaad.2022.03.042 |
| _version_ | 1784677695165038592 |
|---|---|
| author | Pahalyants, Vartan Murphy, William S. Klebanov, Nikolai Lu, Chen Theodosakis, Nicholas Klevens, Monina R. Estiri, Hossein Lilly, Evelyn Asgari, Maryam Semenov, Yevgeniy R. |
| author_facet | Pahalyants, Vartan Murphy, William S. Klebanov, Nikolai Lu, Chen Theodosakis, Nicholas Klevens, Monina R. Estiri, Hossein Lilly, Evelyn Asgari, Maryam Semenov, Yevgeniy R. |
| author_sort | Pahalyants, Vartan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8961936 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | by the American Academy of Dermatology, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89619362022-03-29 Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated” Pahalyants, Vartan Murphy, William S. Klebanov, Nikolai Lu, Chen Theodosakis, Nicholas Klevens, Monina R. Estiri, Hossein Lilly, Evelyn Asgari, Maryam Semenov, Yevgeniy R. J Am Acad Dermatol JAAD Online by the American Academy of Dermatology, Inc. 2022-07 2022-03-29 /pmc/articles/PMC8961936/ /pubmed/35364217 http://dx.doi.org/10.1016/j.jaad.2022.03.042 Text en © 2022 by the American Academy of Dermatology, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | JAAD Online Pahalyants, Vartan Murphy, William S. Klebanov, Nikolai Lu, Chen Theodosakis, Nicholas Klevens, Monina R. Estiri, Hossein Lilly, Evelyn Asgari, Maryam Semenov, Yevgeniy R. Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated” |
| title | Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated” |
| title_full | Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated” |
| title_fullStr | Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated” |
| title_full_unstemmed | Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated” |
| title_short | Reply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated” |
| title_sort | reply to: “covid-19 vaccination in imid patients receiving rituximab: a personalized regimen should be formulated” |
| topic | JAAD Online |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961936/ https://www.ncbi.nlm.nih.gov/pubmed/35364217 http://dx.doi.org/10.1016/j.jaad.2022.03.042 |
| work_keys_str_mv | AT pahalyantsvartan replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT murphywilliams replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT klebanovnikolai replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT luchen replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT theodosakisnicholas replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT klevensmoninar replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT estirihossein replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT lillyevelyn replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT asgarimaryam replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated AT semenovyevgeniyr replytocovid19vaccinationinimidpatientsreceivingrituximabapersonalizedregimenshouldbeformulated |